Degevma (denosumab-adet) has received FDA approval as a biosimilar to Xgeva, demonstrating bioequivalence in safety, efficacy, and immunogenicity. The Food and Drug Administration (FDA) has approved ...

Researchers found an association between increased risk for incidence and progression of diabetic nephropathy in patients with type 2 diabetes.

A bladder-sparing active surveillance program reported on outcomes in patients with muscle-invasive bladder cancer (MIBC).

GLP-1 receptor agonist use in patients with diabetes aims to mitigate cardiovascular kidney and metabolic risk.

Researchers found that use of certain catheter-associated urinary tract infection prevention practices has improved over time in the US.

Hydralazine daily doses greater than 200 mg can be associated with severe overlapping autoimmune syndromes, including lupus erythematosus and ANCA-associated vasculitis. A 71-year-old man presented ...

A study showed that certain pregnancy complications are associated with an increased risk for cardiometabolic-renal conditions in subsequent years.

Although cannabis and CBD can offer modest symptom relief for chronic pain, health care providers should counsel patients on outcomes and drug interactions before use. For health care providers who ...

A meta-analysis of randomized trials supports intensive blood pressure lowering in chronic kidney disease (CKD) not on dialysis.

Patients with intermediate-risk prostate cancer who can safely forgo androgen deprivation therapy (ADT) may be spared its quality-of-life effects.

An observational study suggests benefit from glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in end-stage kidney ...

Classical and collapsing patterns accounted for most de novo FSGS lesions in kidney allografts, which frequently showed chronic tubulointerstitial injury.